Mark van Houdenhoven
YOU?
Author Swipe
View article: Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends Open
Background: Factors like the number of biosimilar competitors and competitive pricing strategies from originator companies may influence price competition and biosimilar uptake. Objective: The aim of this study was to analyze multiple face…
View article: Reverse innovation in western healthcare: a randomised crossover trial comparing the ReMotion prosthetic knee with the current standard of care
Reverse innovation in western healthcare: a randomised crossover trial comparing the ReMotion prosthetic knee with the current standard of care Open
Introduction Healthcare expenses are reaching unaffordable levels worldwide and reverse innovation could play a role in decreasing these expenses and improving healthcare accessibility. The ReMotion Knee, a prosthetic knee primarily develo…
View article: Determinants of drug prices: a systematic review of comparison studies
Determinants of drug prices: a systematic review of comparison studies Open
Objective In this systematic review on drug price comparison studies, we report on recent determinants of drug prices in a national and international context to facilitate regulation of drug prices by purchasers and policymakers worldwide.…
View article: QALY-time: experts’ view on the use of the quality-adjusted life year in cost-effectiveness analysis in palliative care
QALY-time: experts’ view on the use of the quality-adjusted life year in cost-effectiveness analysis in palliative care Open
Background The Quality-Adjusted Life Year (QALY) is internationally recognized as standard metric of health outcomes in cost-effectiveness analyses (CEAs) in healthcare. The ongoing debate concerning the appropriateness of its use for deci…
View article: QALY-Time: Experts’ View On The Use Of The Quality-Adjusted Life Year In Cost-Effectiveness Analysis In Palliative Care
QALY-Time: Experts’ View On The Use Of The Quality-Adjusted Life Year In Cost-Effectiveness Analysis In Palliative Care Open
Background. The Quality-Adjusted Life Year (QALY) is internationally recognized as standard metric of health outcomes in cost-effectiveness analyses (CEAs) in healthcare. The ongoing debate concerning the appropriateness of its use for dec…
View article: Analysing actual prices of medical products: a cross-sectional survey of Dutch hospitals
Analysing actual prices of medical products: a cross-sectional survey of Dutch hospitals Open
Objectives To assess whether there is a difference between the net prices of medical products used by Dutch hospitals and, if there is, how this difference can be explained. Design Cross-sectional self-administered electronic survey. Setti…
View article: QALY-Time: Experts’ view on the use of the quality-adjusted life year in cost-effectiveness analysis in palliative care
QALY-Time: Experts’ view on the use of the quality-adjusted life year in cost-effectiveness analysis in palliative care Open
Background. The Quality-Adjusted Life Year (QALY) is internationally recognized as standard metric of health outcomes in cost-effectiveness analyses (CEAs) in healthcare. The ongoing debate concerning the appropriateness of its use for dec…